炎性肌病中调节性T细胞的IL-2剥夺状态及低剂量IL-2的恢复作用
研究探讨了多发性肌炎(PM)和皮肌炎(DM)患者调节性T细胞(Treg)的IL-2轴是否存在可逆缺陷。结果显示患者CD25hi Treg和CXCR5+ Treg频率降低,尤其活动性肌炎;低剂量IL-2体外选择性上调Treg的CD25表达,两例难治性患者接受低剂量IL-2治疗8周后肌酶下降伴CD25+ Treg持续扩增。提示IL-2缺乏在PM/DM中具有病理生理相关性,低剂量IL-2恢复Treg可能是有前景的靶向治疗。
要点
- PM/DM患者CD25hi Treg和CXCR5+ Treg频率降低,活动性肌炎更明显。
- 低剂量IL-2体外选择性增强Treg的CD25表达并上调免疫调节分子mRNA。
- 两例难治性PM/DM患者低剂量IL-2治疗8周后肌酶下降伴CD25+ Treg扩增。
核心结论
- IL-2短缺在PM/DM中具有病理生理相关性。
- 低剂量IL-2恢复和扩增Treg可能是PM/DM有前景的靶向治疗选择。
研究设计与样本
- 病例对照研究:PM/DM患者20例与健康对照19例,用多色流式细胞术分析CD4+ T细胞亚群。
- 8例患者外周血单个核细胞(PBMC)体外以不同浓度重组人IL-2刺激24小时。
- 6例IL-2刺激PBMC用实时PCR定量IL2RA、IL2RB、ENTPD1、IKZF2、CTLA4 mRNA。
- 两例难治性PM/DM患者接受低剂量IL-2治疗8周并监测临床反应和Treg亚群变化。
主要发现
- PM/DM患者CD25hi Treg频率较健康对照降低(P=0.0052),CXCR5+ Treg频率降低(P=0.0661)。
- 活动性肌炎患者CD25hi Treg降低(P=0.0036),CXCR5+ Treg降低(P=0.0335)。
- 低剂量IL-2刺激选择性增强Treg的CD25分子表达,CD25hi Treg亚群增加(P<0.05)。
- 低剂量IL-2刺激增强多种免疫调节分子mRNA表达(P<0.05)。
- 两例难治性患者低剂量IL-2治疗8周诱导肌酶下降并伴CD25+ Treg持续扩增。
关键数值与推荐
- PM/DM患者CD25hi Treg频率较HC降低,P=0.0052。
- PM/DM患者CXCR5+ Treg频率较HC降低,P=0.0661。
- 活动性肌炎患者CD25hi Treg降低,P=0.0036;CXCR5+ Treg降低,P=0.0335。
- 低剂量IL-2刺激后CD25hi Treg增加及免疫调节分子mRNA表达上调,均P<0.05。
临床怎么用
- 低剂量IL-2可能通过恢复Treg成为PM/DM的靶向治疗选项。
- 监测CD25hi Treg和CXCR5+ Treg频率可能有助于评估疾病活动性。
- 难治性PM/DM患者可考虑低剂量IL-2治疗并监测肌酶和Treg变化。
局限性
- 低剂量IL-2治疗仅两例难治性患者,样本量小。
- 体外刺激实验部分指标样本量有限(mRNA定量n=6)。
- 缺乏长期疗效和安全性数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Regeneration and expansion of Treg by low-dose interleukin-2 (IL-2) therapy is considered a potential treatment strategy for a wide range of autoimmune diseases. To provide a pathophysiologically-based rationale for low-dose IL-2 therapy, we investigated whether reversible defects in the Treg-IL-2 axis emerge in inflammatory myopathies. METHODS: CD4+ T cell subsets from patients with polymyositis (PM) or dermatomyositis (DM) (n = 20) and healthy controls (HC) (n = 19) and peripheral blood mononuclear cells (PBMC) from eight patients that were stimulated in vitro for 24 hours with different concentrations of recombinant human IL-2 were analyzed by multicolor flow cytometry. Messenger RNA (mRNA) expressions of IL2RA, IL2RB, IL2RB, ENTPD1, IKZF2, and CTLA4 were quantified by real-time polymerase chain reaction in IL-2 stimulated PBMC (n = 6). Two patients with refractory PM/DM were treated with low-dose IL-2 therapy for eight weeks and monitored for clinical responses and changes in Treg subsets. RESULTS: Frequencies of Treg expressing CD25 at high levels (CD25hi Treg) and of CXCR5+ Treg were reduced in patients with PM/DM compared with HC (P = 0.0052; P = 0.0661), particularly in active myositis (P = 0.0036; P = 0.0335). Stimulation with low doses of IL-2 selectively enhanced expression of CD25 molecules by Treg, leading to an increase in the CD25hi Treg subset (P < 0.05) and augmented mRNA expression of several immunoregulatory molecules (P < 0.05). Low-dose IL-2 therapy induced decreases in muscle enzymes that were accompanied by a sustained expansion of CD25+ Treg. CONCLUSION: Our data suggest that shortage of IL-2 is pathophysiologically relevant in PM/DM. Recovery and expansion of Treg by low-dose IL-2 therapy could thus be a promising targeted treatment option.
引用
- Ohmes J, Monne LR, Comdühr S, et al. Interleukin-2 Deprived State of Regulatory T cells and Their Recovery by Low-Dose Interleukin-2 in Patients With Inflammatory Myopathies. Arthritis Rheumatol. 2026. PMID: 41882982. doi:10.1002/art.70151
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。